Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Gilead to $84 from $88 and keeps an Equal Weight rating on the shares. In offering a 2024 outlook for North American Biopharma, the firm says it expects four themes – diabesity, product cycles, policy and rates – to be in focus next year. At the stock level, the firm expects “another year of dispersion” and generally recommends investors continue to focus on companies that can deliver growth in the second half of the decade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GILD:
- Ideaya Biosciences enters clinical study pact, supply agreement with Gilead
- Gilead management to meet with Oppenheimer
- Cabaletta Bio, Gracell slide as FDA probes risk of CAR T cell immunotherapies
- FDA probing risk of T-cell malignancy following CAR T cell immunotherapies
- Aurinia strength may be related to Gilead suspicion, says Gordon Haskett